Jinhe Biotechnology CO., LTD. (SHE:002688)
4.550
-0.020 (-0.44%)
Nov 13, 2026, 3:04 PM CST
SHE:002688 Revenue
Jinhe Biotechnology CO., LTD. had revenue of 646.73M CNY in the quarter ending September 30, 2026, with 0.12% growth. This brings the company's total for the last twelve months to 2.94B, up 6.79% year-over-year. In the year 2025, Jinhe Biotechnology CO., LTD. had annual revenue of 2.88B with 21.41% growth. That makes Jinhe Biotechnology CO., LTD. the 12,014th largest company in the world by revenue and 2,065th in China.
Revenue (ttm)
2.94B
Revenue Growth
+6.79%
P/S Ratio
1.17
Revenue / Employee
1.08M
Employees
2,713
Market Cap
3.44B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:002688 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.88B | 507.47M | 21.41% |
| Dec 31, 2024 | 2.37B | 196.50M | 9.04% |
| Dec 31, 2023 | 2.17B | 51.43M | 2.42% |
| Jan 1, 2023 | 2.12B | 44.72M | 2.15% |
| Jan 1, 2022 | 2.08B | 263.35M | 14.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 21.33B |
| Zhejiang Starry Pharmaceutical | 2.61B |
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.70B |
| Qianjiang Yongan Pharmaceutical | 1.15B |
| Tibet Weixinkang Medicine | 1.09B |
| Shandong Wohua Pharmaceutical | 781.18M |
| Newland Pharmaceutical | 733.72M |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 710.26M |